Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D1VX | ISIN: CA25245D1033 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
DIAGNAMED HOLDINGS CORP Chart 1 Jahr
5-Tage-Chart
DIAGNAMED HOLDINGS CORP 5-Tage-Chart

Aktuelle News zur DIAGNAMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoDiagnamed Holdings Corp: Diagnamed expands hydrogen energy extraction with buy1
DoDiagnaMed Holdings Corp.: DiagnaMed Expands Clean Hydrogen Energy Extraction Capabilities to Demonstrate Proof of Concept of Proprietary Technology1
DIAGNAMED Aktie jetzt für 0€ handeln
29.05.Diagnamed Holdings Corp: Diagnamed acquires 91 claims in Ontario1
29.05.DiagnaMed Holdings Corp.: DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District173TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction...
► Artikel lesen
14.04.Diagnamed Holdings Corp: Diagnamed Holdings closes $397,510 offering2
14.04.DiagnaMed Holdings Corp.: DiagnaMed Announces Closing of LIFE Offering191Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions for...
► Artikel lesen
01.04.Diagnamed Holdings Corp: Revive agrees to buy Diagnamed's molecular hydrogen IP1
01.04.Revive Therapeutics Ltd: Revive agrees to buy Diagnamed's molecular hydrogen IP7
04.03.Diagnamed Holdings Corp: Diagnamed's molecular hydrogen named orphan drug by FDA3
04.03.Revive Therapeutics Ltd: Revive to buy molecular hydrogen rights from Diagnamed2
04.03.Diagnamed Holdings Corp: Revive to buy molecular hydrogen rights from Diagnamed1
03.03.DiagnaMed Holdings Corp.: DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis216Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solutions...
► Artikel lesen
28.02.Diagnamed Holdings Corp: Diagnamed arranges minimum $350,000 LIFE offering2
27.02.Diagnamed Holdings Corp: Diagnamed keen to help push Quebec's hydrogen efforts1
27.02.DiagnaMed Holdings Corp.: DiagnaMed Announces LIFE Offering of up to $510,000406Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions...
► Artikel lesen
27.02.DiagnaMed Holdings Corp.: DiagnaMed To Support Quebec's Hydrogen Ambitions Through its Collaboration with QIMC202Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solutions...
► Artikel lesen
19.02.Diagnamed Holdings Corp: Diagnamed talks hydrogen energy tech efforts-
22.01.Diagnamed Holdings Corp: Diagnamed partners with TerraVent Environmental1
22.01.DiagnaMed Holdings Corp.: DiagnaMed and TerraVent Announce Strategic Collaboration for Next-Generation Clean Hydrogen Production1TORONTO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a leading provider of innovative technology solutions for the cleantech...
► Artikel lesen
15.01.DiagnaMed Collaborating With Texas Tech On Hydrogen Innovation1
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1